Brokerages Set Septerna, Inc. (NASDAQ:SEPN) Target Price at $26.75

Key Points

• Septerna, Inc. has received an average rating of "Moderate Buy" from five ratings firms, with one analyst recommending a hold and four recommending a buy.
• The company's stock has seen a price target increase, with Cantor Fitzgerald raising their target to $25.00 and Wells Fargo to $18.00 recently.
• For the last quarter, Septerna reported an EPS of ($0.56), missing expectations significantly, and generated revenue of only $0.12 million against an expected $22.50 million.

Septerna, Inc. (NASDAQ:SEPN - Get Free Report) has earned an average recommendation of "Moderate Buy" from the five ratings firms that are covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 12-month price target among analysts that have covered the stock in the last year is $26.75.

Several brokerages recently weighed in on SEPN. Wells Fargo & Company lifted their price target on Septerna from $11.00 to $18.00 and gave the company an "equal weight" rating in a research report on Friday, May 16th. Cantor Fitzgerald upped their target price on Septerna from $20.00 to $25.00 and gave the stock an "overweight" rating in a research note on Friday, May 16th. Wall Street Zen downgraded Septerna from a "hold" rating to a "sell" rating in a research note on Saturday. Finally, HC Wainwright initiated coverage on Septerna in a research note on Monday, June 23rd. They set a "buy" rating and a $26.00 target price for the company.

Septerna Price Performance

SEPN stock traded up $0.16 during trading on Friday, hitting $11.09. 164,622 shares of the company traded hands, compared to its average volume of 239,568. The stock's 50-day simple moving average is $11.58 and its 200 day simple moving average is $9.09. The company has a market cap of $494.39 million and a PE ratio of -1.10. Septerna has a 1 year low of $4.17 and a 1 year high of $28.99.

Septerna (NASDAQ:SEPN - Get Free Report) last announced its quarterly earnings results on Monday, August 11th. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.51). The company had revenue of $0.12 million for the quarter, compared to analysts' expectations of $22.50 million. Septerna had a negative net margin of 12,053.03% and a negative return on equity of 31.52%. Research analysts expect that Septerna will post -7.11 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Bank of America Corp DE acquired a new position in shares of Septerna during the 4th quarter worth approximately $1,803,000. JPMorgan Chase & Co. acquired a new position in shares of Septerna during the 4th quarter worth approximately $871,000. Jane Street Group LLC acquired a new position in shares of Septerna during the 4th quarter worth approximately $600,000. MetLife Investment Management LLC acquired a new position in shares of Septerna during the 4th quarter worth approximately $265,000. Finally, Barclays PLC acquired a new position in shares of Septerna during the 4th quarter worth approximately $659,000.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.